Clinical Trial Update: Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 immuno-PET imaging study of GSK2849330 in HER3-positive solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK2849330

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer, Neoplasms | Phase 1 | Status: COMPLETED